BiomX Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 26, 2025, details a material definitive agreement entered into by BiomX Inc. (PHGE), a Delaware corporation headquartered in Ness Ziona, Israel. The filing reports a private placement transaction intended to raise capital through the issuance of convertible preferred stock and warrants.
Key Financial Metrics and Transaction Details
- Expected Gross Proceeds: $3.0 million (before deducting placement agent fees and offering expenses).
- Securities Issued: 3,300 shares of Series Y Convertible Preferred Stock with an aggregate stated value of $3.3 million ($1,000 per share).
- Warrants Issued: Warrants to purchase up to 3,300,000 shares of Common Stock (200% of shares issuable upon conversion).
- Dividend Rate: 15% per annum on the stated value of Series Y Preferred Stock, payable quarterly in cash or stock at the investor's election.
- Placement Agent Fees: 7.0% cash fee, 1.0% management fee, $25,000 for non-accountable expenses, plus warrants for 99,000 shares.
- Expected Closing Date: On or about December 30, 2025.
Material Changes and Governance
The transaction introduces significant changes to the company's capital structure and governance:
- Board Expansion: The board will increase by one seat immediately, with the Investor designating a new director. A second director may be designated upon obtaining stockholder approval if the Investor beneficially owns at least 19.99% of outstanding Common Stock.
- Stockholder Approval Requirement: The Company must hold a stockholders' meeting within 60 days of closing to approve the issuance of Common Stock resulting from conversion and warrant exercise, as the aggregate issuance exceeds 19.99% of outstanding shares under NYSE American rules.
- Conversion and Exercise Price Adjustments: The initial conversion and exercise price is $2.00. Following stockholder approval, this price will be reduced to the lower of the current price or the closing sale price of Common Stock immediately prior to approval.
- Registration Rights: The Company must file a resale registration statement within 30 days of closing and use commercially reasonable efforts to have it declared effective within 60 days (or 90 days if reviewed by the SEC).
Outlook, Risks, and Contingencies
The filing contains forward-looking statements regarding the expected closing of the transaction, the timing of the registration statement effectiveness, and the intention to file a proxy statement. Key risks and contingencies include:
- Closing Conditions: The transaction is subject to customary closing conditions.
- Regulatory and Approval Risks: Delays in filing or effectiveness of the Registration Statement, or failure to obtain required stockholder approval.
- Beneficial Ownership Limitations: Prior to stockholder approval, conversion and exercise are prohibited if the holder would beneficially own more than 19.99% of outstanding Common Stock.
- Market Risks: The warrants are not listed on any national securities exchange, and there is no established public trading market for them.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $3.0 million gross proceeds.
- Monitor the filing of the proxy statement and the outcome of the required stockholder vote within 60 days of closing.
- Review the Certificate of Designations for Series Y Preferred Stock to confirm specific anti-dilution provisions and dividend payment mechanics.
- Track the filing and effectiveness status of the resale registration statement for the warrants and convertible shares.
- Assess the impact of the 15% dividend obligation on the company's future cash flow and liquidity.